

**PATENT** 



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Suhrbier, et al.

Serial No.: 09/576,101

Filed: May, 22 2000

For: POLYEPITOPE VACCINES

Group Art Unit: 1644

Examiner: Huynh, P. N.

Atty. Dkt. No.: FBRC:004USC1/TMB


### Appendix D

SUBSTITUTE DRAWINGS SHEETS 1/29 THROUGH 29/29



APPROVED O.G. F.IG.
BY CLASS SUCCLASS
DRAFTSMAN

1/29



MSTNSFLRGRAYGL QAKWRLQTL-EENLLDFVRF SVRDRLARLKEHVIQNAF-YPLHEQHGMHLAAQGMAY DTPLIPLTIF-IVTDFSVIK NNLVSGPEH

Polytope Protein Sequence

EFFECTOR CTL CLONES




SUBCLASS APPLIOVED 12.G. F.G. BY OLASS SU. DRAFTSMAN

% Specific Lysis








YW22 CM4 **NB26** JSA2 CM9 **CS31** EBNA 6 TK Polytope EBNA 3 TK Polytope EBNA 6 TK Polytope EBNA 3 TK Polytope EBNA 2 TK Polytope EBNA 4 TK Polytope

> Recombinant Vaccinias

FIGURE 2




PRAFTS ! AN



% Specific Lysis

FIGURE 3






FIGURE 4



JC48 35

NOV 2 5 2002

Kozac CCACC GGATCC BamHI

Start XbaI SR

GCC AGC AAC GAG AAC ATG GAC GCC ATG Σ Α Ο Σ Ш z s ⋖ ATG TCTAGA

AGC ATC ATC AAC TTC GAG AAG CIT Z

ACC TAC CAG AGG ACC AGG GCC CTG GTG AGC GAC TAC GAG GGC AGG CTG ATC > 0 × ۲ ۷ ~ ~

Ш С Ж

TAC CCA CAC TTC ATG CCT ACC AAC CTG Δ Σ μ I ۵

AGT GGG CCC AGT AAC ACC CCG CCA GAG ATC Δ ۵ ഗ م ACTAGT SpeI T S

> S GCC CCA GGC AAC TAC CCT GCC CTG ⋖ Δ. Z U 4

AGC TAC ATC CCA AGC GCC GAG AAG ATC ш ح S

5/29

GAG AGA GGG GCC ATC GTG GGC GAG ATC AGG CCT CAG GCC AGC GGC GTG TAC ATG SalI A S G Stop ~ Mab epitope Ш **U** >

**U** 

工 Ш LVSGP Z ~

CCTAGG

<u>Δ</u>

AvrII


GTCGAC TAG AAC AAC CTG GTG TCC GGC CCC GAG GAC TTA

FIGURE 5





### Flu NP "TYQRTRALV" (H-2K<sup>d</sup>)




Effector: Target Ratio

LEGEND	Bulk Splenocytes from Polytope Vaccinated Mice
	No peptide Control
<del></del>	Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6A



### PB csp "SYIPSAEKI" (H-2K<sup>d</sup>)



Effector: Target Ratio

LEGEND

—□— Bulk Splenocytes from Polytope Vaccinated Mice


—△— No peptide Control

—○— Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6B



### MCMV pp89 "YPHFMPTNL" (H-2L<sup>d</sup>)



Effector: Target Ratio

LEGEND

—□— Bulk Splenocytes from Polytope Vaccinated Mice

—△— No peptide Control


—O— Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6C





### LCMV NP "RPQASGVYM" (H-2K<sup>d</sup>)



LEGEND

—□— Bulk Splenocytes from Polytope Vaccinated Mice


—△— No peptide Control

—○— Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6D

APPLOVED CLAUS SUBOLASS PARFISMAN

### Flu NP "SDYEGRLI" $(H-2K^k)$



Effector: Target Ratio

LEGEND ————	Bulk Splenocytes from Polytope Vaccinated Mice
	No peptide Control
<del>-</del> 0-	Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6E


0.G. FIG.

CLASS

DRAFTSMAN

11/29





**Effector: Target Ratio** 

LEGEND

——— Bulk Splenocytes from Polytope Vaccinated Mice


——— No peptide Control

———— Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6F



### Flu NP "ASNENMDAM" (H-2Db)



Effector: Target Ratio

LEGEND

—□— Bulk Splenocytes from Polytope Vaccinated Mice


—△— No peptide Control

—○— Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6G



### Ad5 E1A "SGPSNTPPEI" (H-2D<sup>b</sup>)



Effector: Target Ratio

LEGEND

—□— Bulk Splenocytes from Polytope Vaccinated Mice

—△— No peptide Control

—□— Bulk Splenocytes from TK- Vaccinated Mice


FIGURE 6H



DRAFTSMAN

14/29

### Ovalbumin "SIINFEKL" (H-2K<sup>b</sup>)



LEGEND

—□ Bulk Splenocytes from Polytope Vaccinated Mice

—△ No peptide Control


Bulk Splenocytes from TK- Vaccinated Mice

FIGURE 6I



### Sendi NP "FAPGNYPAL" (H-2K<sup>b</sup>)





Effector: Target Ratio

FIGURE 6J



APPROVED O.G. FIG.
BY CLASS SUBCLASS

DRAFTS:MAN





FIGURE 7





Effector: Target Ratios
50:1 //////
10:1 \_\_\_\_\_\_
2:1

FIGURE 8a






FIGURE 8b




FIGURE 8c





VIRUS INFECTED TARGETS




FIGURE 9a





VIRUS INFECTED TARGETS




FIGURE 96



APPROVED O.G. H.G.
BY CLASS SUCCLASS

DRAFTSMAN

# PEPTIDE COATED TARGETS

MCMV pp89 "YPHFMPTNL"

1001

80

9

40

% Specific Lysis

20

4

# VIRUS INFECTED TARGETS

Vacc Mu PT Vacc Hu PT 4  $\mathsf{C}^{\scriptscriptstyle 1}$ Vaccinia Infected Targets 80 2 8 20 4 30 20 10 0 % Specific Lysis Peptide Coated No Peptide

22/29

FIGURE 9c

Effector: Target Ratio

Effector: Target Ratio

10

20

0





VIRUS INFECTED TARGETS





FIGURE 9d






## VIRUS INFECTED TARGETS



24/29

FIGURE 9e









FIGURE 9f





VIRUS INFECTED TARGETS




FIGURE 9g



DRAFTS172

### PEPTIDE COATED TARGETS




FIGURE 9h



### A7PROVED 13 C. F. BV DIASS SULCIALS

# PEPTIDE COATED TARGETS





FIGURE 9i








FIGURE 9j